OncoTricks

Clots, blood and melanoma, Oct 12, 2026

Antiphospholipid syndrome: suspect, prove, anticoagulate

If you remember one thingClot or pregnancy loss, antibody still positive at 12 weeks, then warfarin, not a direct oral anticoagulant.

When to think of it

ClotsVenous clot without a cause in a young patient.
Clot in an unusual site.
Stroke or heart attack in a young patient.
A new clot while on apixaban or rivaroxaban.
PregnancyThree or more losses before 10 weeks.
A fetal death at 10 weeks or later.
Delivery before 34 weeks for preeclampsia or a failing placenta.
Clues on the chartProlonged partial thromboplastin time with no bleeding.
Low platelets. Lupus.
Livedo (net-like purple skin). Thick heart valves.

The diagnosis: one event, one test, twice

A clot or a pregnancy complication+A positive test→The same test positive again, 12 weeks or more later→Antiphospholipid syndrome
1
Lupus anticoagulant. A clotting test, run by two methods (dilute Russell viper venom time and a sensitive partial thromboplastin time). Unreliable during an acute clot and on any anticoagulant (see the test board of Oct 9).
2
Anticardiolipin, IgG or IgM. Above 40 units or above the 99th percentile.
3
Anti-beta-2 glycoprotein I, IgG or IgM. Above the 99th percentile.

Positive in all three is called triple positive: the highest-risk profile. Tests 2 and 3 are antibody tests and can be drawn on any anticoagulant. The event and the positive test must fall within 5 years of each other (2006 criteria) or 3 years (2023 criteria).

Who gets what

A clot or stroke yet?
no
Low-dose aspirin, 75 to 100 mgRecommended with a high-risk profile (triple or double positive, lupus anticoagulant, persistently high titers). May be considered otherwise. Triple-positive people who had never clotted had a first clot at 5.3% a year (104 people, mean 4.5 years; Pengo 2011).
yes
Arterial: stroke or heart attack?
yes
Warfarin, INR 2 to 3Or INR 3 to 4, or INR 2 to 3 plus aspirin, weighing bleeding against recurrence
no, venous
Did the first venous clot have a clear cause?
yes
Warfarin, INR 2 to 3, usual durationLonger with a high-risk profile
no
Warfarin, INR 2 to 3, indefinitely

INR is the clotting-time ratio used to dose warfarin.

Triple positive, or any arterial event→No rivaroxaban, no apixaban

Against warfarin, direct oral anticoagulants tripled new clots, mostly arterial.5 randomized trials, 624 patients: 29 clots against 10, Peto odds ratio 3.01; arterial 5.5; venous no different (Adelhelm 2023). A direct oral anticoagulant is a fallback only for venous, not triple-positive disease when warfarin is impossible or the INR cannot be kept in range.

Clot on warfarin at INR 2 to 3→Check adherence and recent INRs→INR 3 to 4, or full-dose enoxaparin, or add aspirin

Pregnancy

Pregnancy complications only, no clot ever

Aspirin 75 to 100 mg, ideally before conception→+ prophylactic enoxaparin (40 mg daily) through delivery→Prophylactic enoxaparin 6 weeks after

Prior clot, on warfarin

Switch to enoxaparin before week 6→Full weight-based dose + aspirin until delivery→Full-dose enoxaparin after delivery, then back to warfarin for life

Warfarin harms the embryo from week 6 and is safe during breastfeeding. Direct oral anticoagulants are not used in pregnancy. A positive test with no events: aspirin may be considered. When losses continue despite treatment: raise enoxaparin to full dose, or add hydroxychloroquine, or add low-dose prednisolone in the first trimester. In women with antibodies and recurrent losses, heparin plus aspirin raised live births over aspirin alone (risk ratio 1.27; 5 trials, 1,295 women; low-certainty evidence); for enoxaparin-type heparin alone the estimate was 1.20.

Classification criteria are not a diagnosis
  • The 2023 ACR/EULAR criteria (American College of Rheumatology and European League Against Rheumatism) score six clinical and two laboratory domains and need 3 points in each.
  • Built for research: 99% specific but 84% sensitive, against 86% and 99% for the 2006 criteria. A patient who misses them can still need treatment.
  • How often the tests are positive, by event: stroke 13.5%, heart attack 11%, deep vein thrombosis 9.5%, pregnancy complications 6% (median across 120 studies).
Catastrophic antiphospholipid syndrome
  • Clots in three or more organs within days, usually small vessels: kidney, lung, brain. Under 1% of patients with the syndrome, often after an infection.
  • Death in 37% of 522 episodes in the international registry.
  • Treatment is combined from the start: heparin + glucocorticoids + plasma exchange or immunoglobulin.
Check yourself: antiphospholipidA 38-year-old has an unprovoked femoral clot. The lupus anticoagulant comes back positive the day after rivaroxaban was started. Diagnosis made?

No. Rivaroxaban causes false-positive lupus anticoagulant results, and one test is never enough. Send anticardiolipin and anti-beta-2 glycoprotein I now (reliable on any anticoagulant), and repeat at 12 weeks. Repeat the lupus anticoagulant off anticoagulant, or ask the lab for a DOAC-neutralized assay; many labs can do this.

Sources

Retrieved from PubMed (abstracts and full text), read on Oct 15, 2026.

  1. Miyakis S, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006. doi:10.1111/j.1538-7836.2006.01753.x
  2. Barbhaiya M, et al. The 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis 2023. doi:10.1136/ard-2023-224609
  3. Andreoli L, et al. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis. Arthritis Care Res 2013. doi:10.1002/acr.22066
  4. Devreese KMJ, et al. Update of the guidelines for lupus anticoagulant detection and interpretation (ISTH). J Thromb Haemost 2020. doi:10.1111/jth.15047
  5. Tektonidou MG, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019. doi:10.1136/annrheumdis-2019-215213
  6. Zuily S, et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: ISTH guidance. J Thromb Haemost 2020. doi:10.1111/jth.14935
  7. Adelhelm JBH, et al. Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: systematic review and meta-analysis of randomised trials. Lupus Sci Med 2023. doi:10.1136/lupus-2023-001018
  8. Pengo V, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome (TRAPS). Blood 2018. doi:10.1182/blood-2018-04-848333
  9. Woller SC, et al. Apixaban compared with warfarin in thrombotic antiphospholipid syndrome (ASTRO-APS). Blood Adv 2022. doi:10.1182/bloodadvances.2021005808
  10. Pengo V, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile. Blood 2011. doi:10.1182/blood-2011-03-340232
  11. Sammaritano LR, et al. 2020 ACR guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 2020. doi:10.1002/art.41191
  12. Hamulyák EN, et al. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst Rev 2020. doi:10.1002/14651858.CD012852.pub2
  13. Rodríguez-Pintó I, et al. Catastrophic antiphospholipid syndrome: descriptive analysis of 500 patients from the international registry. Autoimmun Rev 2016. doi:10.1016/j.autrev.2016.09.010